Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure – - 50% Response Rate at the Selected Dose Level of 30 ...
The biggest problem is the problem that plagues seemingly all prequels: the fact that no matter how far back in the past the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback